©The Author(s) 2018.
World J Hepatol. Sep 27, 2018; 10(9): 549-557
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.549
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.549
Table 2 Direct-acting antiviral regimens available to treat hepatitis C virus genotype 4
| 1Combination regimen[43,44] | Duration (wk) |
| Sofosbuvir-ledipasvir | 12 |
| Sofosbuvir-velpatasvir | 12 |
| Glecaprevir-pibrentasvir | 8 (without cirrhosis) |
| 12 (with cirrhosis) | |
| Sofosbuvir-velpatasvir-voxilaprevir | 12 |
| Ombitasvir-paritaprevir-ritonavir ± ribavirin | 12 |
| Elbasvir-grazoprevir ± ribavirin | 12-16 |
| Elbasvir-grazoprevir | 12 (treatment naïve) |
| Elbasvir-grazoprevir + ribavirin | 16 (treatment experienced) |
| Sofosbuvir + ribavirin | 24 |
| Sofosbuvir + daclatasvir ± ribavirin | 12 |
| Sofosbuvir + simeprivir ± ribavirin | 12-24 |
- Citation: Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557
- URL: https://www.wjgnet.com/1948-5182/full/v10/i9/549.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i9.549